Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes
Kelly S. Chien, Guillermo Garcia-Manero(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Hui Yang(Hebei Medical University), Yue Lyu(The University of Texas MD Anderson Cancer Center), Yesid Alvarado Valero(The University of Texas MD Anderson Cancer Center), Marianne Zoghbi(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Danielle Hammond(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Ziyi Li(The University of Texas MD Anderson Cancer Center), Xiao Qin Dong(The University of Texas MD Anderson Cancer Center), Akhil Jain(The University of Texas MD Anderson Cancer Center), Tapan Kadia(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k